SUMMARY
Buprenorphine, an opioid partial agonist, is some 30 times more potent than morphine [1] . It is metabolized to buprenorphine-3-glucuronide (B3G) and to norbuprenorphine (N-dealkyl buprenorphine) (NorB) [2] ; both metabolites have been found in plasma following long term administration in man [1] . A third metabolite, a conjugate of N-dealkyl buprenorphine, is found also in human urine [3] .
The pharmacokinetics of i.v. buprenorphine have been described previously [4] over a 3-h sampling period, with a mean clearance of 901 ml min" 1 in anaesthetized patients. The main site of metabolism of buprenorphine appears to be the liver, and therefore impaired renal function should not result in alterations of plasma drug disposition. However, the absence of renal function may lead to plasma accumulation of metabolites as has been reported following single i.v. and multiple doses of opioids such as morphine [5] [6] [7] [8] , codeine [9] , pethidine [10, 11] and propoxyphene [12] .
The present paper describes two complementary studies examining the disposition of buprenorphine and its two main metabolites in patients with normal renal function and those with renal failure. In the single dose study, buprenorphine 0.3 mg was given i.v. as part of a balanced anaesthetic technique; in the multiple dosing study, 20 patients received the drug by variable rate infusion to provide analgesia during controlled ventilation in the intensive care unit.
PATIENTS AND METHODS
All 35 patients (or their relatives) from whom data were collected gave their informed consent to participation in the investigations, which were approved by the Central Oxford Research Ethics Committee.
Single dose study
We studied nine patients with renal failure and six anaesthetized control subjects with normal renal function undergoing lower abdominal or body surface surgery. All patients with renal failure (table I) were dialysis-dependent, with preoperative creatinine clearances less than 5 ml min" 1 . All underwent dialysis within 6-20 h of the start of surgery. Four of these nine patients were receiving antihypertensive therapy, including beta-adrenoceptor blocking drugs.
Preoperative plasma urea and creatinine concentrations in those patients with normal renal function ranged between 3.3 and 6.5 mmol litre" 1 and 85 and 103 umol litre" 1 , respectively. Premedication comprised diazepam 10-15 mg 2 h before surgery. Patients in the renal failure group who were receiving beta-adrenoreceptor blocking or other antihypertensive drugs received their normal daily dose at 06:00 and additional therapy, where appropriate, with the premedication.
Anaesthesia was induced with thiopentone 4 mg kg" 1 and the trachea intubated after neuromuscular block with atracurium 0.25 mg kg" 1 . The patient's lungs were ventilated to normocapnia using a Bain circuit with a tidal volume of 10 ml kg" 1 and a fresh gas flow of 70 ml kg" 1 min" patients. Sedation was provided by increments of midazolam or diazepam, the aim being to achieve compliance with the ventilator, but response to verbal or tactile stimulation. Blood samples for measurement of buprenorphine and metabolite concentrations were collected from an indwelling arterial cannula at the same time as routine biochemistry and haematology samples (usually 08:00 and 16:00).
Sample analysis
Plasma samples were analysed for buprenorphine and metabolites (B3G and NorB) by a differential radioimmunoassay technique which utilized an iodinated buprenorphine derivative with two anti-buprenorphine antisera (LI60, LI62 rabbit antibuprenorphine antisera, Reckitt and Colman) with differing cross-reactivities [1] . LI60 measured buprenorphine and cross-reacting B3G; LI62 measured buprenorphine and NorB. The molar cross-reactivity to B3G (compared with buprenorphine) was 69% using the LI60 antiserum, and that to NorB 0.3%; for L162, NorB cross-reacted 92%, and B3G 1.5%. The sensitivity for the two assays waŝ 0.2 nmol litre" 1 for all three compounds, and the dynamic range of the buprenorphine assay was 2-60 nmol litre"
1 . The inter-assay coefficient of variation for buprenorphine using each antiserum was 7.7-18.0% over the range 2-11 nmol litre" 1 . Concentrations measured during the present studies were 0.2-11 nmol litre"
1 . An extraction procedure (to remove buprenorphine from plasma containing the more polar B3G) coupled to the radioimmunoassay gave a specific measurement of buprenorphine without interference from the metabolite; recovery following extraction was 98-100%. All samples from one patient were analysed during single assay series.
When using LI60 antiserum without extraction, a standard curve of B3G was included in each assay together with the buprenorphine standard, to allow for inter-assay variability in cross-reactivity. The same was done for the L162 antiserum and NorB.
Plasma concentrations of urea and creatinine, enzyme activities and serum concentrations of bilirubin were measured by standard laboratory methods using a Technicon RA 100 Analyser.
Kinetic and statistical analyses
Following a single i.v. dose, the elimination half-life was determined by non-linear regression analysis of the concentration-time data from the 30-min sample. The area under the concentration-time curve (AUC) and its first moment (AUMC) were calculated by the linear trapezoidal method and from these, model-independent estimates were made of clearance, apparent volume of distribution at steady state and mean residence time (C/ P , V, MRT).
Following multiple dosing, buprenorphine clearance was calculated by division of 1000 times the infusion rate over the previous 8 h (in nmol min" 1 ) by the plasma buprenorphine concentration (in nmol litre" 1 ) [13] . To obtain an average estimate for buprenorphine clearance for each patient, the mean of all measured 8-h clearance values for an individual was calculated.
For correlation with plasma creatinine concentrations, buprenorphine and metabolite concentrations were converted to dose-related values by division of the plasma concentration by the average dose of buprenorphine infused per hour over the previous 8-h period.
Data within the two patient groups were compared using the Mann-Whitney U test, and results are shown as mean (SD) or median and range, as appropriate. Correlation between plasma urea or creatinine and plasma buprenorphine or metabolite concentrations, or buprenorphine clearance, were carried out using the Spearman rank correlation coefficient. The significance value for differences between groups was P < 0.05.
RESULTS

Single dose study
Anaesthesia and surgery were uneventful in all patients. Plasma buprenorphine concentrations declined in a curvilinear manner in both patient groups. There were no secondary peaks on the concentration decay profiles. Comparison of LI 60 extracted, LI60 non-extracted and LI62 assayed samples showed no difference in plasma concentrations of buprenorphine. Elimination half-lives were 148-694 min in patients with normal renal function and 101-560 min in patients with impaired renal function (ns). Associated derived kinetic parameters are shown in table II. There was wide inter-individual variability between subjects, and no significant differences for the kinetic parameters between groups, with the exception of MRT (P < 0.05). In patients with renal failure, there were no significant correlations Buprenorphine by infusion provided adequate analgesia and control of ventilation in most patients, as judged clinically by the nursing staff, although there was occasional need for supplementation with other drugs (papaveretum, neuromuscular blocking agents). Table IV gives the individual infusion rates, durations of infusion, and total dose of buprenorphine infused. The median infusion rate was 161 ugh" 1 (MSnmolh" 1 ) (range 32-230 ugh" 1 ) and the median duration of infusion was 30 h (range 2-565 h). Two severely ill patients (Nos 5 and 6) received large doses of buprenorphine for 284 and 565 h, respectively, and one (No. 5) was given a total of 18770 ng during a 24-h period. There were no associated unexpected changes in hepatic or renal function suggestive of toxicity, or exaggerated central nervous system depression. The infusion was discontinued and the patient given morphine for terminal care. Plasma concentrations of buprenorphine metabolites following dose correction are shown in table V. Dose-related plasma buprenorphine concentrations were similar for both patient groups, but dose-related plasma concentrations of the two metabolites were increased in those patients with renal impairment. There was a median four-fold increase for NorB and a median 15-fold increase for B3G (P < 0.001 for both metabolites).
The 12 patients with normal renal function had a mean (SD) buprenorphine clearance of 934 (385) ml min-1 (range 371-1614 ml min" 1 ); the eight with impaired renal function had a similar mean clearance (1103 (515) ml min" 1 (445-2032 ml min" 1 )). When data from all 20 patients were analysed together, there was no correlation between plasma creatinine and dose-related plasma concentrations of buprenorphine. Statistically significant linear relationships with low correlation coefficients were found between plasma creatinine and dose-related B3G concentrations (y = 0.0012x-0.0332; r = 0.40, P < 0.0001, n = 92); and between plasma creatinine and dose-related NorB concentrations (y = 0.000131 x + 0.0227; r = 0.328, P < 0.0001, n = 92). Plasma concentrations of buprenorphine increased with the rate of infusion of buprenorphine (nmol min" 1 as an average of the previous 8h; y = 0.472.x+ 2.46; r = 0.414, P < 0.0001, n = 110).
There were no significant correlations between plasma concentrations of buprenorphine and each metabolite. However, the plasma concentrations of the two metabolites were closely related (y = 0.129x + 2.78; r = 0.933, P < 0.0001, n = 120) ( fig. I )- In none of the 20 patients were there sideeffects or adverse effects attributable to the opioid.
DISCUSSION
The disposition and metabolism of buprenorphine in man and animals have been studied principally by use of radiolabelled buprenorphine. In all species investigated, the major portion (about 70%) of oral or parenteral doses of the drug is excreted in the faeces [14, 15] -mostly as unchanged buprenorphine [14] . There is, in addition, some evidence for enterohepatic recirculation in man [15] .
Little unchanged buprenorphine was recovered from the urine, where the metabolites buprenorphine-3-glucuronide (B3G) norbuprenorphine (NorB) and N-dealkyl buprenorphine-3-glucuronide were present. Between 2 and 13% of a dose of buprenorphine was found in the urine, the extent depending on the route of administration [15] . After a single i.v. dose of 0.6 mg, both conjugated buprenorphine and the N-dealkyl metabolite were found in urine for up to 7 days [3] .
Plasma concentrations of buprenorphine after single doses by the i.v., i.m., sublingual and oral routes of administration have been documented [4, 16, 17] . However, there are few data on the plasma disposition of buprenorphine and its metabolites in either healthy patients or those with disordered renal function. A previous study reported the disposition of buprenorphine to be " unaltered in renal failure; however, that study was limited to a 3-h sampling period, and measured only parent drug [18] . The present single dose study in anaesthetized patients has confirmed the earlier observations. There were immeasurable concentrations of buprenorphine within 12-24 h of a single i.v. dose, and the concentrations of the two metabolites in blood were either zero or below the limit of sensitivity of the assay [1] . Comment should be made on the variability in clearance values and elimination half-lives in the single dose part of this study. Earlier reports have indicated a coefficient of variation (CV) for clearance of the order of 22% [ 1 ] , while the C V in the healthy patient group in the present study was 46%, and that in the impaired renal function group, 49 %. The increased variability may reflect several differences between the two studies: wider age and weight ranges, the influence of various intercurrent drug therapies, different surgical operations, different vascular sampling sites and longer duration of sampling. In addition, there is the possible competitive interaction between buprenorphine and the premedicant diazepam for the same metabolic pathway.
After long term administration, however, plasma concentrations of NorB were of the same order as those of the parent drug; while the concentrations of B3G were some two-fold greater [1] . These interesting results, despite infusion rates of the parent drug of only 50-250 ug h" 1 , may be interpreted as indicating that the elimination kinetics of the metabolites were non-linear with respect to the parent compound. Plasma concentrations of B3G decreased at a rate similar to those of buprenorphine, whilst those of NorB declined more slowly. This is in agreement with the slower appearance of NorB in urine [3] . B3G is analgesically inactive, while NorB is some 40 times less potent as an analgesic than buprenorphine when assessed using the rat tailflick test [Lloyd-Jones G, personal communication].
Systemic clearance of buprenorphine would not be expected to be related to renal function, as buprenorphine clearance is considered to occur mainly by hepatic extraction and metabolism [2, 14, 19] . In contrast to the parent drug, the dose-related plasma concentrations of B3G and NorB were both increased when given by infusion to patients with renal impairment. The marked linear relationship between the two metabolites ( fig. 1 ) may indicate that these compounds are eliminated by a similar route, which is most likely to be different from that of the parent drug.
Plasma concentrations of B3G were approximately 10-fold greater than those of NorB ( fig. 1) , and this may reflect the further metabolism of the latter to a conjugated form [15] . Conjugated NorB has been detected in human urine [3] , but would not have been so by the differential assay used in this present study. The concentrations of NorB found in our intensive care patients with impaired renal function are unlikely to have exerted significant pharmacological activity, given the lower potency of the metabolites and lower receptor affinity compared with the parent drug.
